Amgen

Open: 267.71 Close: 269.64 Change: 1.93

Are you looking for information about Amgen Stock? We programmed an AI to summarize it for you.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, AMGN, Patent, Tuesday, trade, AWS, infrastructure, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen Inc. stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. Amgen earlier this month acquired Horizon Therapeutics for $27.8 billion.

Today's News

Amgen shares up fractionally in Tuesday afternoons trading. New partnership calls for Amgen to put AWS infrastructure tools to use for advanced assembly and final product packaging. Amgen Inc. is trending stock amgen inc. (amgn) a buy now? Amgen is rated Zacks Rank #3 (Hold) Amgen reported revenues of $6.9 billion in the last reported quarter, representing a year-over-year change of +3.8%. Amgen to present at the Evercore ISI HealthCONx Conference at 9:10 a.m. on November 22, 2023. Amgen is also using AWS global infrastructure to support its new digital data and analytics platform. Amgen Inc. stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. Amgen earlier this month acquired Horizon Therapeutics for $27.8 billion. Amgen is a biotechnology company which discovers, develops, manufactures, and markets innovative human medicines. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. U.S. Supreme Court will tackle Patent Enablement In Amgen Case. Amgen (NQ: AMGN ) 269.64 +3.04 (+1.04%) Streaming Delayed Price Updated: 4:00 PM EST, Nov 30, 2022. Amgen (NASDAQ:AMGN) posted Q1 earnings of $1.48 billion, an increase from Q4 of 22.27%. Shares of Amgen are trading down 5.5% over the last 24 hours, at $2.6 billion. Amgen (AMGN) is in the Health Care sector and Biotechnology industry. Amgen has the highest number of patents in rare diseases followed by data science and artificial intelligence. European Patent Office (E/P) Patent Office dominates the patent filings and grants.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, AMGN, Patent, Tuesday, trade, AWS, infrastructure, and the most common words in the summary are: amgen, stock, amazon, news, company, top, data, . One of the sentences in the summary was: stock AMGN, +0.62% rose 2.9% in premarket trade Tuesday, after the biotech blew past earnings estimates for the third quarter and again raised its guidance. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #amazon #news #company #top #data.